Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Collier Neurologic Specialists LLC

Neither a doctor nor a teaching hospital

Research payments

$873,565

132 payments

Through program year 2025, Collier Neurologic Specialists LLC is reported as receiving $873,565 in research payments, across 132 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $5,063 2
2024 Research $3,849 6
2023 Research $17,637 16
2022 Research $371,357 32
2021 Research $260,088 37
2020 Research $101,107 21
2019 Research $114,465 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $495,058 12 payments
  2. Genentech, Inc. $105,865 16 payments
  3. Genzyme Corporation $86,629 31 payments
  4. EMD Serono, Inc. $56,518 35 payments
  5. Novartis Pharmaceuticals Corporation $44,269 2 payments
  6. ACADIA Pharmaceuticals Inc $41,083 11 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $14,713 2 payments
  8. Amneal Pharmaceuticals LLC $11,000 2 payments
  9. Ucb SA $10,350 2 payments
  10. Mallinckrodt Hospital Products Inc. $3,686 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $382,268 6 payments
  2. Effect of Ly3154207 on Cognition in Mild to Moderate Parkinsons Disease Dementia PDD - the Presence Study $107,891 5 payments
  3. Phase II Study for Moderate Ad $105,865 16 payments
  4. A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. $56,518 35 payments
  5. A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $50,259 13 payments
  6. A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $44,269 2 payments
  7. A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) $24,750 12 payments
  8. Acp-103-045 $22,998 7 payments
  9. Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age $10,400 1 payment
  10. A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab Ucb0107 in Study Participants With Prodromal to Mild Alzheimers Disease Ad, Followed By An Open-Label Extensio $10,350 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record